Newborn infants who have hereditary spherocytosis (HS) can develop anemia and hyperbilirubinemia. Bilirubin-induced neurologic dysfunction is less likely in these neonates if the diagnosis of HS is recognized and appropriate treatment provided. Among neonates listed in the USA Kernicterus Registry, HS was the third most common underlying hemolytic condition after glucose-6-phosphate dehydrogenase deficiency and ABO hemolytic disease. HS is the leading cause of direct antiglobulin test (direct Coombs) negative hemolytic anemia requiring erythrocyte transfusion in the first months of life. We anticipate that as physicians become more familiar with diagnosing HS in the newborn period, fewer neonates with HS will develop hazardous hyperbilirubinemia or present to emergency departments with unanticipated symptomatic anemia. We predict that early suspicion, prompt diagnosis and treatment, and anticipatory guidance will prevent adverse outcomes in neonates with HS. The purpose of this article was to review the neonatal presentation of HS and to provide practical and up-to-date means of diagnosing and treating HS in neonates.

Hereditary spherocytosis (HS) is a heterogeneous disorder in which abnormalities of red blood cell structural proteins lead to loss of erythrocyte membrane surface area, resulting in spherical-shaped, hyperdense, poorly deformable red blood cells (Fig 1) with a shortened life span.\textsuperscript{1–5} HS occurs worldwide and affects individuals from all racial and ethnic groups. Individual pediatricians encounter HS uncommonly, but hospitals and health care systems with large delivery services regularly deal with this condition, particularly in white neonates of northern European ancestry, in whom the condition can be as frequent as 1 in 1000 to 2000 births. Early suspicion and diagnosis of HS allow appropriate management, including provision of anticipatory guidance to parents, which can reduce the risk of adverse outcomes.

The purpose of the present article was to review the neonatal presentation of HS and to provide practical and up-to-date means of diagnosing and treating HS in neonates.

PATHOGENESIS

The loss of membrane surface area in HS erythrocytes is due to defects in various erythrocyte membrane proteins, ankyrin-1, band 3, \( \beta \)-spectrin, \( \alpha \)-spectrin, and protein 4.2 (Table 1, Fig 2)\textsuperscript{1–5} Numerous mutations in the genes encoding these membrane proteins have been described. Destruction of poorly deformable HS erythrocytes in the spleen is the primary cause of hemolysis in patients with HS.

The clinical spectrum of HS during the perinatal period ranges from severe fetal anemia with hydrops fetalis to the asymptomatic neonate. This wide
range is due, in part, to the various genes and specific mutations involved, as well as to the presence or absence of co-inherited conditions. For instance, HS coinherited with mutations or polymorphisms of genes involved in bilirubin uptake into hepatocytes ($SLC01B1$) or intrahepatic bilirubin conjugation ($UGT1A1$) can increase the risk of hazardous hyperbilirubinemia and kernicterus.$^6$–$^9$

MAKING THE DIAGNOSIS OF HS IN A NEONATE
As with any relatively uncommon neonatal disorder, the first step in making the diagnosis of HS is considering it in the differential diagnosis. Thus, a basic understanding of HS is useful to physicians caring for neonates. We have found that the triad of anemia, splenomegaly, and jaundice, which is found in older children and adults with HS, is rare in neonates. More than one-half of neonates with HS are not anemic in the first week of life, and splenomegaly is rarely detected.$^{10}$ Jaundice is the most common presenting feature of HS in neonates.$^{11}$ In addition, the typically sluggish erythropoietic response of neonates often renders the reticulocyte count low relative to the degree of anemia$^{10}$; spherocytes are less often observed on the blood smear of neonates; and other markers of hemolysis seen in older patients, such as low haptoglobin levels,$^{12}$ may be poor indicators of hemolysis in the neonate.

Severe neonatal jaundice can be the result of various underlying causes.$^{13}$–$^{16}$ Unfortunately, as illustrated by Johnson et al,$^{13}$ even when hyperbilirubinemia is severe enough to cause kernicterus, the underlying cause of the jaundice frequently remains unidentified. Perhaps the intense focus on reducing the elevated bilirubin level into a safe range sometimes results in neglecting evaluation of how the bilirubin became so high in the first place.$^{14}$

Approximately 65% of neonates with HS have a parent with HS,$^1,^3,^5$ When a parent has HS, it is important that this information be placed prominently in the prenatal record and communicated verbally, before birth, to the physicians and the hospital staff who will be providing neonatal care. All parents with HS should be encouraged to communicate this information to their infant’s physician before delivery. Failure to do so sometimes occurs when the affected parent has been asymptomatic since undergoing splenectomy as a child and has all but forgotten about the condition, and fails to consider that it might be problematic for the newborn infant. It can be helpful to specifically inquire of parents of anemic and/or jaundiced neonates about a family history of anemia, jaundice, splenectomy, or early gallstones.

One way to suspect HS in a jaundiced neonate is to obtain a complete blood cell count for interpretation of the red blood cell indices, in particular the mean corpuscular hemoglobin concentration (MCHC) and the mean corpuscular volume (MCV), and to examine the peripheral blood smear for the presence of spherocytes and polychromasia.$^{17}$ Typically, a neonate with HS will have an elevated MCHC. Figure 3 displays the histograms of MCHC measurements in 3 groups of jaundiced neonates: (1) direct antiglobulin test (DAT)-negative jaundice; (2) DAT-positive jaundice (primarily ABO hemolytic disease); and (3) HS. The histogram reveals some overlap in MCHC, but, as

### TABLE 1 Erythrocyte Membrane Proteins Involved in HS

<table>
<thead>
<tr>
<th>Protein</th>
<th>Gene</th>
<th>Chromosomal Location</th>
<th>Percentage of HS Cases</th>
<th>Typical Severity</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ankyrin-1</td>
<td>ANK1</td>
<td>8p11.2</td>
<td>40–50</td>
<td>Mild to moderate</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Band 3</td>
<td>SLC4A1</td>
<td>17q21</td>
<td>20–35</td>
<td>Mild to moderate</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>β-spectrin</td>
<td>SPTB</td>
<td>14q23-24.1</td>
<td>15–30</td>
<td>Mild to moderate</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>α-spectrin</td>
<td>SPTA1</td>
<td>1q22-23</td>
<td>&lt;5</td>
<td>Severe</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Protein 4.2</td>
<td>EPB42</td>
<td>15q15-21</td>
<td>&lt;5</td>
<td>Mild to moderate</td>
<td>Autosomal recessive</td>
</tr>
</tbody>
</table>
If a neonate’s MCHC is elevated (>36.5 to 37 g/dL), HS is likely.11 Another way to estimate whether a neonate has HS takes advantage of the fact that in most neonates with HS, the MCV is low. Based on this scenario, the neonatal HS ratio can be calculated by dividing the MCHC by the MCV. Using this ratio, little overlap is seen between normal neonates and those later proven to have HS. In fact, in the Intermountain Healthcare database, a neonatal HS ratio >0.36 indicates that HS is present with 97% sensitivity, >99% specificity, and >99% negative predictive value.18 It is likely that different makes and models of automated cell counters generate slight differences in erythrocyte indices, such as the MCV and MCHC. Validation of the neonatal HS ratio on all models of counters would be useful. The mean hemoglobin content of all the measured red blood cells as well as reticulocyte parameters can sometimes be helpful in suggesting HS,19 but we are unaware of reports of their use in newborn infants.

Figure 4 reviews our recommendations for how to evaluate a neonate for HS when a parent is known to have HS. Because the common forms of HS are inherited in an autosomal dominant manner, each child born to a parent with HS has a 50% chance of inheriting the disorder. The key element in the algorithm is to treat the neonate as if he or she has HS until proven otherwise. In addition to obtaining erythrocyte indices, this approach includes peripheral smear examination and reticulocyte count, adhering to the American Academy of Pediatrics’ guidelines for bilirubin monitoring in the birth hospital, aggressive phototherapy when indicated, and a follow-up bilirubin assessment no later than 24 hours after the hospital discharge.20,21

The presence of spherocytes on peripheral blood smear is helpful when considering the diagnosis of HS (Fig 1),14 but up to one-third of neonates with HS do not have spherocytes identified prominently on their blood smear. Some neonates with band 3 deficiency have pincered red blood cells.22 A subset of neonates with DAT-negative ABO incompatibility severe enough to produce spherocytes on peripheral smear have been described. In most cases, the differentiation from HS is
clear (e.g., family history, maternal/infant blood group analysis), but additional testing such as elution of anti-A or anti-B from neonatal erythrocytes or detection of free anti-A or anti-B immunoglobulin G antibody in neonatal serum (indirect Coombs test) can clarify the diagnosis.

When the diagnosis of HS is uncertain, eosin-5-maleimide (EMA) binding or osmotic fragility testing can be helpful23–25 (Fig 6). EMA binding is a flow cytometry–based test that measures the relative amount of fluorescently labeled EMA dye bound to band 3 and Rh-related proteins in the erythrocyte membranes. In HS, the reduction in band 3 and other membrane proteins leads to decreased fluorescence intensity. In the Primary Children’s Hospital hematology clinic, EMA flow has outperformed other diagnostic tests for HS in newborn infants.24 Neonatal erythrocytes exhibit altered response to osmotic stress compared with adult erythrocytes. However, after incubation, osmotic fragility has been successfully used to diagnose HS in neonates26,27 New flow cytometric methods of assessing erythrocyte osmotic fragility are promising28–30 but we do not have experience with these methods for diagnosing HS in newborn infants nor do we know of published studies in

FIGURE 3
Frequency distribution of MCHC (grams per deciliter) values in 3 groups of jaundiced neonates: (1) DAT negative (Coombs negative); (2) DAT positive (Coombs positive); and (3) HS. (Reprinted with permission from Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia. Pediatrics. 2010;125(1):124).

FIGURE 4
Evaluating a neonate during the birth hospitalization whose parent has HS. The evaluation includes the following: (1) observe the serum bilirubin level and treat according to the American Academy of Pediatrics’ guidelines during and for several days after the birth hospitalization as if this were a known case of hemolysis; (2) during the birth hospitalization initiate the evaluation as given in the graphic or as suggested by hematology consultation; and (3) consider that the neonate could have more severe jaundice than the parent did as a neonate, particularly if there has been coinheritance of a polymorphism-retarding bilirubin uptake or conjugation. CBC, complete blood cell count.

When the diagnosis of HS is uncertain, eosin-5-maleimide (EMA) binding or osmotic fragility testing can be helpful23–25 (Fig 6). EMA binding is a flow cytometry–based test that measures the relative amount of fluorescently labeled EMA dye bound to band 3 and Rh-related proteins in the erythrocyte membranes. In HS, the reduction in band 3 and other membrane proteins leads to decreased fluorescence intensity. In the Primary Children’s Hospital hematology clinic, EMA flow has outperformed other diagnostic tests for HS in newborn infants.24 Neonatal erythrocytes exhibit altered response to osmotic stress compared with adult erythrocytes. However, after incubation, osmotic fragility has been successfully used to diagnose HS in neonates26,27 New flow cytometric methods of assessing erythrocyte osmotic fragility are promising28–30 but we do not have experience with these methods for diagnosing HS in newborn infants nor do we know of published studies in
which these methods were proven effective with the blood of neonates. Sodium dodecyl sulfate polyacrylamide gel electrophoresis has been used as well but has generally been replaced by other methods.31

Table 2 lists laboratory evaluations we consider to be helpful in diagnosing HS in a neonate. Sequencing of the relevant genes can be performed as a confirmatory test (available in a few reference laboratories) when desired.32 We reserve genetic sequencing for cases with no family history and a severe HS phenotype. The goal would be to make a clear diagnosis, allow for appropriate therapy, and to provide parents and family members with genetic information for counseling regarding risk of recurrence.

**TREATMENT**

Phototherapy should reduce the bilirubin level of jaundiced neonates with HS, and it is the mainstay of treatment in the first days after birth.33–35 When a bilirubin level is found to be in the high or high to intermediate risk zone (>75th percentile reference interval), phototherapy should be provided immediately. An exchange transfusion followed by intensive phototherapy should follow American Academy of Pediatrics’ guidelines.20,21,36

When signs of anemia appear, packed erythrocyte transfusions are helpful. Longitudinal studies indicate that transfusion requirements abate in most patients by 1 year of age. The few patients who remain transfusion dependent (typically those with severe anemia in utero or immediately after birth) experience severe HS. In a few reports, recombinant erythropoietin (rEPO, or long-acting darbepoetin rEPO) therapy has been used as an alternative or adjunct to transfusion.37–39 The rationale for rEPO treatment relates to the relative hypoplastic phase of erythropoiesis during the first weeks to months after birth. This phase might be associated with the abrupt decrease after birth from the highly stimulated erythropoiesis during fetal life, the switch of erythropoietin (EPO) production from the liver to the kidney, the switch from fetal to adult hemoglobin, or a lower serum level of EPO in infants compared with older children. Patients with moderate or severe HS should receive folate supplementation to prevent complications of folic acid deficiency. Splenectomy is rarely undertaken in the first year of life. Because
hemolysis abates in most patients, careful symptomatic management is prudent, with transfusion therapy as indicated.

**NATURAL HISTORY OF HS DURING INFANCY**

This topic has received relatively little attention in published series or reviews. Delhommeau et al. reported on 34 infants with HS during their first year of life, and neonatal jaundice was present in virtually all of the infants. Twenty-seven infants were treated with phototherapy, and 3 received exchange transfusions in the first week due to hyperbilirubinemia. Thirty-one of the 34 infants had pallor and dyspnea during the first week due to hyperbilirubinemia. Thirty-one of the 34 infants had pallor and dyspnea during the first week due to hyperbilirubinemia.

Not needed to diagnosis most cases of HS. However, it can establish the diagnosis in difficult cases. Consider sequencing of relevant genes when family history is negative and severe DAT-negative hemolysis is idiopathic.

**REFERENCES**

preterm Hispanic twins led to the diagnosis of hereditary spherocytosis in them, and in their sibling and in their mother. J Perinatol. 2011;31(9):625–627


34. Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol. 2011;35(3):101–113


GETTING THE LAST DROP: Our refrigerator is littered with partially filled bottles of mustard, ketchup, and mayonnaise. In order to get the last of the ingredient, I will store them in such a way that promotes flow of the material toward the nozzle. Despite my best efforts, however, far too much mustard or ketchup remains stuck in the bottle and unusable. It would appear that others have the same problem.

Consumer Reports magazine reported in September 2009 that a considerable amount of what we buy, from toothpaste to laundry detergent, cannot be used as it remains trapped in the container. Their tests showed that 25 percent of skin lotion and 15 percent of condiments such as mustard and ketchup are thrown away. Help, however, may be on the way.

As reported in The New York Times (Science: March 23, 2015), a Massachusetts Institute of Technology professor and one of his graduate students have developed a coating for the inside of containers to make them slippery. When a fluid moves through a pipe or a container, the layer next to the pipe usually sticks to it and does not move. The fluid farthest from the wall of the pipe or container moves fastest. The trick is to make the boundary between the wall of the container and the first layer of fluid slippery with a lubricant. The MIT scientists developed an equation to predict the interactions between the surface of the container, the lubricant, and air and water. The lubricant binds more strongly to the surface of the container than to the liquid, allowing the liquid to slide on a layer of lubricant rather than over the surface of the container. The first successful application of the equation was in developing a lubricant that allows glue to flow effortlessly through a glue bottle. The materials can be modified for different applications. For instance, specific coatings can be developed to help crude oil, toothpaste, and honey flow more easily in their containers.

While the industrial applications are impressive, I am particularly happy that I will not be wasting as much food in the future; I expect food applications to appear in 2017.

Noted by WVR, MD
A Pediatrician's Practical Guide to Diagnosing and Treating Hereditary Spherocytosis in Neonates

Robert D. Christensen, Hassan M. Yaish and Patrick G. Gallagher

Pediatrics 2015;135;1107; originally published online May 25, 2015;
DOI: 10.1542/peds.2014-3516

Updated Information & Services
including high resolution figures, can be found at:
/content/135/6/1107.full.html

References
This article cites 41 articles, 9 of which can be accessed free at:
/content/135/6/1107.full.html#ref-list-1

Post-Publication Peer Reviews (P3Rs)
One P3R has been posted to this article:
/cgi/eletters/135/6/1107

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Hematology/Oncology
/cgi/collection/hematology:oncology_sub
Blood Disorders
/cgi/collection/blood_disorders_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2015 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
A Pediatrician's Practical Guide to Diagnosing and Treating Hereditary Spherocytosis in Neonates

Robert D. Christensen, Hassan M. Yaish and Patrick G. Gallagher

*Pediatrics* 2015;135;1107; originally published online May 25, 2015;
DOI: 10.1542/peds.2014-3516

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/135/6/1107.full.html